natgillin/translations-raw huggingface dataset:
Canine parainfluenza Type 2 virus, strain CPiV Bio 15
Virus pasje parainfluence tipa 2, sev CPiV-Bio 15
Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 - 105.1 TCID50*/ml
Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15 103,1 - 105,1 TCID50*/ml
Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 - 105.1 TCID50*/ml
Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15 103,1 -105,1 TCID50
Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 _ 105.1 TCID50*/ml Canine adenovirus type 2, strain CAV-2 Bio 13 103.6 – 105.3 TCID50*/ml Canine parvovirus type 2b, strain CPV-2b Bio 12/B 104.3 – 106.6 TCID50*/ml Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 – 105.1 TCID50*/ml
Virus pasje kuge, sev CDV Bio 11/A 103,1 -105,1 TCID50* Virus pasjega adenovirusa tipa 2, sev CAV-2 Bio 13 103,6 -105,3 TCID50* Virus pasjega parvovirusa tipa 2b, sev CPV-2b Bio 12/B 104,3 -106,6 TCID50* Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15 103,1 -105,1 TCID50
Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 103.1 TCID50* 105.1 TCID50
Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15 103,1 TCID50* 105,1 TCID50
Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 103.1 TCID50* 105.1 TCID50*
Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15 103,1 TCID50* 105,1 TCID50
Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 103.1 – 105.1 TCID50*/ml
Virus pasje parainfluence tipa 2, sev CPiV-2 Bio 15 103,1 - 105,1 TCID50
canine parainfluenza virus and canine adenovirus type 2, which cause kennel cough; leptospirosis, a bacterial disease that may be transmitted via infected urine and results in bleeding, hepatitis (inflammation of the liver) and jaundice or nephritis (kidney inflammation).
virusom pasje parainfluence in pasjim adenovirusom tipa 2, ki povzročata kužni kašelj; leptospirozo, tj. bakterijsko boleznijo, ki se lahko prenaša z okuženim urinom in povzroči krvavitve, hepatitis (vnetje jeter) in zlatenico ali nefritis (vnetje ledvic).
Canine parainfluenza virus Type 2
Virus pasje kuge
Canine parainfluenza virus vaccine (live attenuated)
cepivo proti virusu pasje parainfluence (živo, atenuirano)
canine parainfluenza virus, which causes kennel cough;
virusom pasje parainfluence, ki povzroča kužni kašelj;
canine parainfluenza virus, which causes kennel cough; leptospirosis, a bacterial disease that may be transmitted via infected urine and result in bleeding, hepatitis (inflammation of the liver) and jaundice or nephritis (kidney inflammation).
virusom pasje parainfluence, ki povzroča kužni kašelj; leptospirozo, tj. bakterijsko boleznijo, ki se lahko prenaša z okuženim urinom in povzroči krvavitve, hepatitis (vnetje jeter) in zlatenico ali nefritis (vnetje ledvic).
canine parvovirus disease, an infection that may severely affect puppies, resulting in lethargy, fever, vomiting and bloody diarrhoea; canine parainfluenza virus and canine adenovirus type 2, which cause kennel cough.
boleznijo, ki jo povzroča pasji parvovirus, tj. okužbo, ki lahko močno prizadene pasje mladiče in povzroči letargijo, povišano telesno temperaturo, bruhanje in krvavo drisko; virusom pasje parainfluence in pasjim adenovirusom tipa 2, ki povzročata kužni kašelj.
Cannot be administered in pregnant or lactating pigs.
Mešanice ne smete dajati brejim ali doječim svinjam.
Cannot be sold separately.
Ni namenjeno izdajanju posamično.
cannot keep food or water in your body because of severe nausea and vomiting
ne morete v sebi zadržati hrane ali tekočine zaradi hude slabosti in bruhanja
Canyon Pharmaceuticals Limited 7th Floor
Canyon Pharmaceuticals Limited, 7th Floor
Can’t be sold separately.
Prodaja posamezne enote ni možna.
Can’t be sold separately.
Prodaja posameznega dela ni mogoča.
cap
in
Cap
pokrovček
Cap
zaporka
Cap Clip
Deli KwikPena
Cap Clip
Sponka pokrovčka
Cap Inspection window Internal needle cover
pokrovček pregledno okence notranje pokrivalo igle
Cap Lid
zaporka poklopec
cap Polyproylene
zaporko Polipropilen
Cap scale
Kazalnik odmerkov
Cap scale
on on
Cap scale
Telo peresnika
Cap the developing tanks.
Pokrijte generatorja za razvijanje.
Cap: light blue opaque printed ‘M’ axially in black ink.
Pokrovček: svetlo modre barve s črnim napisom “M” v smeri osi kapsule.
Cap: Protective cap is on the dual vial unit.
Zaporka: Zaščitna zaporka je na enoti z dvema vialama.
Capecitabine Accord 150 mg and 500mg film-coated tablets
Kapecitabin Accord 150 mg in 500 mg filmsko obložene tablete
Capecitabine Accord 150 mg film-coated tablets
Kapecitabin Accord 150 mg filmsko obložene tablete
Capecitabine Accord 150 mg film-coated tablets are light peach coloured, oblong shaped, biconvex, film-coated tablets of 11.4 mm in length and 5.3 mm in width, debossed with ‘150’ on one side and plain on other side.
Kapecitabin Accord 150 mg filmsko obložene tablete so svetlo breskove barve, podolgovate oblike, bikonveksne, filmsko obložene tablete dolžine 11,4 mm in debeline 5,3 mm z vtisnjeno oznako “150” na eni strani in brez oznake na drugi strani.
Capecitabine Accord 150 mg film-coated tablets Capecitabine Accord 300 mg film-coated tablets Capecitabine Accord 500 mg film-coated tablets capecitabine
Kapecitabin Accord 150 mg filmsko obložene tablete Kapecitabin Accord 300 mg filmsko obložene tablete Kapecitabin Accord 500 mg filmsko obložene tablete kapecitabin
Capecitabine Accord 300 mg film-coated tablets are white to off white, oblong shaped, biconvex, film-coated tablets of 14.6 mm in length and 6.7 mm in width, debossed with ‘300’ on one side and plain on other side.
Kapecitabin Accord 300 mg filmsko obložene tablete so bele ali kremne bele barve, podolgovate oblike, bikonveksne, filmsko obložene tablete dolžine 14,6 mm in debeline 6,7 mm z vtisnjeno oznako “300” na eni strani in brez oznake na drugi strani.
Capecitabine Accord 500 mg film-coated tablets
Kapecitabin Accord 500 mg filmsko obložene tablete
Capecitabine Accord 500 mg film-coated tablets are peach coloured, oblong shaped, biconvex, film-coated tablets of 15.9 mm in length and 8.4 mm in width, debossed with ‘500’ on one side and plain on other side.
Kapecitabin Accord 500 mg filmsko obložene tablete so bele ali kremne bele barve, podolgovate oblike, bikonveksne, filmsko obložene tablete dolžine 15,9 mm in debeline 8,4 mm z vtisnjeno oznako “500” na eni strani in brez oznake na drugi strani.
Capecitabine Accord dose calculations
Odmerek zdravila Kapecitabin Accord
Capecitabine Accord is a ‘hybrid generic medicine’.
Zdravilo Capecitabine Accord je „hibridno generično zdravilo“.
Capecitabine Accord is available in blister packs (Aluminium/Aluminium or PVC/PVdC/Aluminium) containing 30, 60 or 120 film-coated tablets or in perforated unit dose blister packs (PVC/PVDC/Aluminium) containing 30 x 1, 60 x 1 or 120 x 1 film-coated tablets.
Zdravilo Kapecitabin Accord je na voljo v pretisnih omotih (aluminijevi/aluminijevi ali PVC/PVdC/aluminijevi) po 30, 60 ali 120 filmsko obloženih tablet ali v perforiranih pretisnih omotih za enkratni odmerek (PVC/PVdC/aluminijevi) po 30 x 1, 60 x 1 ali 120 x 1 filmsko obloženih tablet.
Capecitabine Accord is indicated for the treatment of:
Zdravilo Kapecitabin Accord je indicirano za:
Capecitabine Accord is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area (calculated using the patient’s height and weight).
Zdravilo Capecitabine Accord se jemlje dvakrat na dan v odmerkih med 625 in 1 250 mg na kvadratni meter telesne površine (izračunano glede na bolnikovo višino in telesno maso).
Capecitabine Accord is used with or without other anticancer medicines in patients who have had surgery for ‘stage III’ or ‘Dukes’ stage C’ colon cancer; metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Zdravilo Capecitabine Accord se uporablja z drugimi zdravili proti raku ali samostojno pri bolnikih po operaciji raka kolona stadija III ali stadija Dukes C; metastatskega kolorektalnega raka (raka debelega črevesa, ki se je razširil na druge dele telesa).
Capecitabine Accord is used with or without other anticancer medicines; advanced gastric (stomach) cancer.
Zdravilo Capecitabine Accord se uporablja z drugimi zdravili proti raku ali samostojno; napredovale oblike raka želodca.
Capecitabine Accord is used with other anticancer medicines, including a platinum-containing anticancer medicine such as cisplatin; locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body).
Zdravilo Capecitabine Accord se uporablja z drugimi zdravili proti raku, vključno z zdravilom proti raku, ki vsebuje platino (kot na primer cisplatin); lokalno napredovalega ali metastatskega raka dojke (raka dojke, ki se je začel širiti na druge dele telesa).
Capecitabine Accord tablets should be swallowed with water within 30 minutes after a meal.
Filmsko obložene tablete zdravila Kapecitabin Accord je treba pogoltniti z vodo največ 30 minut po obroku.
Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine.
Kapecitabin in njegovi presnovki se izločajo pretežno z urinom.
Capecitabine dose calculations
Odmerek kapecitabina
Capecitabine dose reduction decreases systemic exposure to 5-FU more than dose- proportionally, due to non-linear pharmacokinetics for the active metabolite.
Če zmanjšamo odmerek kapecitabina, se sistemska izpostavljenost 5-FU zaradi nelinearne farmakokinetike aktivnega presnovka zmanjša bolj kot sorazmerno z odmerkom.
Capecitabine in combination with cisplatin was non-inferior to 5-FU in combination with cisplatin in terms of progression-free survival in the per protocol analysis (hazard ratio 0.81; 95% CI 0.63 - 1.04).
Kapecitabin je bil v kombinaciji s cisplatinom neinferioren kombinaciji 5-FU in cisplatina glede na preživetje brez napredovanja bolezni v analizi po protokolu (razmerje ogroženosti 0,81; 95-% interval zaupanja 0,63–1,04).
Capecitabine in combination with cisplatin was non-inferior to 5-FU in combination with cisplatin in terms of progression-free survival in the per protocol analysis (hazard ratio 0.81; 95% CI 0.63-1.04).
Kapecitabin je bil v kombinaciji s cisplatinom neinferioren kombinaciji 5-FU in cisplatina glede na preživetje brez napredovanja bolezni v analizi po protokolu (razmerje ogroženosti 0,81; 95-% interval zaupanja 0,63–1,04).
Capecitabine is a ‘prodrug’ that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Kapecitabin je „predzdravilo“, ki se v telesu pretvori v 5-florouracil (5-FU), in sicer v večji meri v tumorskih celicah kot v normalnem tkivu.
Capecitabine is a ‘prodrug’ that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Kapecitabin je „predzdravilo“, ki se v telesu pretvori v 5-florouracil (5-FU), vendar v večji meri v tumorskih celicah kot v normalnem tkivu.
Capecitabine is a ‘prodrug’ that is converted to 5-fluorouracil (5-FU) in the body, but more is converted in tumour cells than in normal tissues.
Kapecitabin je „predzdravilo“, ki se v telesu pretvori v 5-fluorouracil (5-FU), in sicer več v tumorskih celicah kot v normalnem tkivu.
Capecitabine is a ‘prodrug’ that is converted to 5-fluorouracil (5-FU) in the body, mainly in tumour cells.
Kapecitabine je „predzdravilo“, ki se v telesu pretvori v 5-fluorouracil (5-FU), in sicer v glavnem v tumorskih celicah.
Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min [Cockcroft and Gault] at baseline).
Zdravilo kapecitabin je kontraindicirano pri bolnikih s hudo ledvično okvaro (očistek kreatinina pod 30 ml/min (Cockcroft in Gault) na začetku zdravljenja).
Capecitabine is not indicated in children and adolescents.
Kapecitabin ni indiciran za otroke in mladostnike.
Capecitabine medac
Kapecitabin medac
Capecitabine Medac is a ‘generic’ and a ‘hybrid’ medicine.
Zdravilo Capecitabine Medac je „generično“ in „hibridno“ zdravilo.
Capecitabine Medac is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area (calculated using the patient’s height and weight).
Jemlje se dvakrat na dan v odmerkih med 625 in 1 250 mg na kvadratni meter telesne površine (izračunane na podlagi bolnikove višine in telesne mase).
Capecitabine Medac is used with or without other anticancer medicines in patients who have had surgery for ‘stage III’ or ‘Dukes’ stage C’ colon cancer; metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Zdravilo Capecitabine Medac se uporablja sočasno z drugimi zdravili proti raku ali kot samostojno zdravilo pri bolnikih po operaciji raka kolona stadija III ali stadija Dukes C; metastatskega kolorektalnega raka (raka debelega črevesa, ki se je razširil na druge dele telesa).
Capecitabine Medac is used with or without other anticancer medicines; advanced gastric (stomach) cancer.
Zdravilo Capecitabine Medac se uporablja skupaj z drugimi zdravili proti raku ali kot samostojno zdravilo; napredovale oblike raka želodca.
Capecitabine monotherapy
Samostojno zdravljenje s kapecitabinom
Capecitabine Monotherapy:
Samostojno zdravljenje s kapecitabinom
Capecitabine Monotherapy:
Samostojno zdravljenje s kapecitabinom:
capecitabine oral twice daily for 2 weeks (followed by 1 week off- treatment)
kapecitabin peroralno dvakrat na dan 2 tedna (sledi 1-tedenski premor)
Capecitabine SUN 150 mg are light peach coloured, oval, biconvex, film-coated tablet debossed with ‘150’ on one side and plain on other side.
Kapecitabin ne 150 mg filmsko obložene tablete so svetlo breskove barve, ovalne, bikonveksne oblike, z vtisnjeno oznako “150” na eni strani in brez oznake na drugi strani.
Capecitabine SUN 150 mg film-coated tablets
Kapecitabin SUN 150 mg filmsko obložene tablete
Capecitabine SUN 150 mg film-coated tablets capecitabine
Kapecitabin SUN 150 mg filmsko obložene tablete kapecitabin
Capecitabine SUN 150 mg film-coated tablets.
Kapecitabin SUN 150 mg filmsko obložene tablete.
Capecitabine SUN 500 mg are peach coloured, oval, biconvex, film-coated tablet debossed with ’500’ on one side and plain on other side.
Kapecitabin ne 500 mg filmsko obložene tablete so svetlo breskove barve, ovalne, bikonveksne oblike, z vtisnjeno oznako “500” na eni strani in brez oznake na drugi strani.
Capecitabine SUN 500 mg film-coated tablets
Kapecitabin SUN 500 mg filmsko obložene tablete
Capecitabine SUN 500 mg film-coated tablets are peach coloured, oval, biconvex, 17.5 mm x 8.7 mm tablets, with inscription ‘500’on one side and plain on other side.
Kapecitabin SUN 150 mg filmsko obložene tablete so breskove barve, ovalne, bikonveksne oblike, velikost 17.5 mm x 8.7 mm, z oznako “500” na eni strani in brez oznake na drugi strani.
Capecitabine SUN 500 mg film-coated tablets capecitabine
Kapecitabin SUN 500 mg filmsko obložene tablete kapecitabin
Capecitabine SUN 500 mg film-coated tablets.
Kapecitabin SUN 500 mg filmsko obložene tablete.
Capecitabine SUN contains anhydrous lactose
Kapecitabin SUN vsebuje brezvodno laktozo
Capecitabine SUN is a ‘generic medicine’.
Zdravilo Capecitabine SUN je „generično zdravilo“.
Capecitabine SUN is not indicated in children and adolescents.
Zdravilo Kapecitabin SUN ni namenjeno otrokome in mladostnikom.
Capecitabine SUN is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area (calculated using the patient’s height and weight).
Zdravilo Capecitabine SUN se jemlje dvakrat na dan v odmerkih med 625 in 1 250 mg na kvadratni meter telesne površine (izračunane na podlagi bolnikove višine in telesne mase).
Capecitabine SUN is used with or without other anticancer medicines in patients who have had surgery for ‘stage III’ or ‘Dukes’ stage C’ colon cancer; metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Zdravilo Capecitabine SUN se uporablja z drugimi zdravili proti raku ali kot samostojno zdravilo pri bolnikih po operaciji raka kolona stadija III ali stadija Dukes C; metastatskega kolorektalnega raka (raka debelega črevesa, ki se je razširil na druge dele telesa).
Capecitabine SUN is used with or without other anticancer medicines; advanced gastric (stomach) cancer.
Zdravilo Capecitabine SUN se uporablja skupaj z drugimi zdravili proti raku ali kot samostojno zdravilo; napredovale oblike raka želodca.
Capecitabine SUN is used with other anticancer medicines, including a platinum-containing anticancer medicine such as cisplatin; locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body).
Zdravilo Capecitabine SUN se uporablja z drugimi zdravili proti raku, vključno z zdravilom proti raku, ki vsebuje platino, kot na primer cisplatin; lokalno napredovalega ali metastatskega raka dojk (raka dojk, ki se je začel širiti na druge dele telesa).
Capecitabine SUN may make you feel dizzy, nauseous or tired.
Zdravilo Kapecitabin SUN lahko povzroči omotico, slabost ali občutek utrujenosti.
Capecitabine SUN tablets should be swallowed with water within 30 minutes after a meal.
Tablete zdravila Kapecitabin SUN je treba pogoltniti z vodo v 30 minutah po obroku.
Capecitabine SUN with food and drink
Zdravilo Kapecitabin SUN skupaj s hrano in pijačo
Capecitabine Teva
Kapecitabin Teva
Capecitabine Teva 150 mg film-coated tablets capecitabine
Kapecitabin Teva 150 mg filmsko obložene tablete kapecitabin
Capecitabine Teva 150 mg film-coated tablets Capecitabine Teva 500 mg film-coated tablets capecitabine
Kapecitabin Teva 150 mg filmsko obložene tablete Kapecitabin Teva 500 mg filmsko obložene tablete kapecitabin
Capecitabine Teva 150 mg film-coated tablets EU/1/12/761/001
Kapecitabin Teva 150 mg filmsko obložene tablete EU/1/12/761/001
Capecitabine Teva 500 mg film-coated tablets
Kapecitabin Teva 500 mg filmsko obložene tablete
Capecitabine Teva 500 mg film-coated tablets capecitabine
Kapecitabin Teva 500 mg filmsko obložene tablete kapecitabin
Capecitabine Teva contains lactose
Zdravilo Kapecitabin Teva vsebuje laktozo
Capecitabine Teva dose calculations
Odmerek zdravila Kapecitabin Teva
Capecitabine Teva film-coated tablets should be swallowed with water within 30 minutes after a meal.
Zdravilo Kapecitabin Teva je treba pogoltniti z vodo v 30 minutah po obroku.
Capecitabine Teva is a ‘generic medicine’.
Capecitabine Teva je „generično zdravilo“.
Capecitabine Teva is indicated for the treatment of:
Zdravilo Kapecitabin Teva je indicirano:
Capecitabine Teva is taken twice a day at doses between 625 and 1,250 mg per square metre body surface area (calculated using the patient’s height and weight).
Zdravilo Capecitabine Teva se jemlje dvakrat na dan v odmerkih med 625 in 1 250 mg na kvadratni meter telesne površine (izračunane na podlagi bolnikove telesne višine in mase).
Capecitabine Teva is used with or without other anticancer medicines in patients who have had surgery for ‘stage III’ or ‘Dukes’ stage C’ colon cancer; metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body).
Zdravilo Capecitabine Teva se uporablja sočasno z drugimi zdravili proti raku ali pa kot samostojno zdravilo pri bolnikih po operaciji raka kolona stadija III ali stadija Dukes C, metastatskega kolorektalnega raka (raka debelega črevesa, ki se je razširil na druge dele telesa).
Capecitabine Teva is used with or without other anticancer medicines; advanced gastric (stomach) cancer.
Zdravilo Capecitabine Teva se uporablja sočasno z drugimi zdravili proti raku ali pa kot samostojno zdravilo, napredovale oblike raka želodca.
Capecitabine Teva is used with other anticancer medicines, including a platinum-containing anticancer medicine such as cisplatin; locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body).
Zdravilo Capecitabine Teva se uporablja sočasno z drugimi zdravili proti raku, vključno z zdravilom proti raku, ki vsebuje platino, kot je na primer cisplatin,
Capecitabine Teva may make you feel dizzy, nauseous or tired.
Zdravilo Kapecitabin Teva lahko povzroči omotico, slabost ali občutek utrujenosti.
Capecitabine Teva with food and drink
Zdravilo Kapecitabin Teva skupaj s hrano in pijačo
Capillary leak
sindrom povečane prepustnosti kapilara
Capillary leak syndrome
sindrom povečane prepustnosti kapilar
Capillary Leak Syndrome due to leakage of blood components through small blood vessel walls - this may cause rapid swelling to arms, legs and other parts of your body, rapid drop in blood pressure, lightheadedness and breathing difficulties.
»Sindrom kapilarnih razpok«, ki je posledica uhajanja krvnih elementov skozi stene kapilar – to lahko povzroča hitro otekanje rok, nog in drugih delov telesa, nenaden padec krvnega tlaka, omotičnost in težave z dihanjem.
Capillary leak syndrome has been reported after administration of G-CSF or derivatives and is characterised by hypotension, hypoalbuminaemia, oedema and haemoconcentration.
Po uporabi G-CSF ali derivatov so poročali o sindromu kapilarne prepustnosti, za katerega so značilni hipotenzija, hipoalbuminemija, edemi in hemokoncentracija.
Capillary leak syndrome has been reported after granulocyte colony-stimulating factor administration and is characterised by hypotension, hypoalbuminaemia, oedema and hemoconcentration.
Po uporabi granulocitne kolonije stimulirajočega faktorja so poročali o sindromu kapilarne prepustnosti, za katerega so značilni hipotenzija, hipoalbuminemija, edemi in hemokoncentracija.
Capillary leak syndrome has been reported after granulocyte colony-stimulating factor administration, and is characterised by hypotension, hypoalbuminaemia, oedema and hemoconcentration.
Po uporabi granulocitne kolonije stimulirajočega faktorja so poročali o sindromu kapilarne prepustnosti, za katerega so značilni hipotenzija, hipoalbuminemija, edemi in hemokoncentracija.
Capillary leak syndrome in pre- existing monoclonal gammopathy*
sindrom zvečane prepustnosti kapilar pri že prisotni monoklonski gamopatiji
Capillary leak syndrome in pre-existing monoclonal gammopathy2
sindrom kapilarne prepustnosti pri obstoječi monoklonalni gamopatiji2
Capillary leak syndrome*
sindrom kapilarne prepustnosti
Capillary leak syndrome*
sindrom kapilarnega prepuščanja
Capillary leak syndrome, hypotension, hypertension
indrom kapilarnih razpok, hipotenzija, hipertenzija
Capillary leak syndrome, which can be life-threatening if treatment is delayed, has been reported mostly in cancer patients undergoing chemotherapy after administration of G-CSF or derivatives (see section 4.4 and subsection “Description of selected adverse reactions” of section 4.8).
Zlasti pri bolnikih z rakom, ki so prejemali kemoterapijo, so po uporabi G-CSF ali derivatov poročali o sindromu kapilarne prepustnosti, ki je lahko smrtno nevaren, če ni zdravljen takoj; glejte poglavje 4.4 in podpoglavje »Opis izbranih neželenih učinkov« poglavja 4.8.
Capillary leak syndrome, which can be life-threatening if treatment is delayed, has been reported uncommonly (≥ 1/1000 to < 1/100) in cancer patients undergoing chemotherapy and healthy donors undergoing peripheral blood progenitor cell mobilisation following administration of granulocyte colony- stimulating factors; see section 4.4 and subsection C of section 4.8.
Občasno (≥ 1/1000 do < 1/100) so pri bolnikih z rakom, ki so prejemali kemoterapijo, in po izplavljanju matičnih celic v periferno kri pri zdravih dajalcih po uporabi granulocitne kolonije stimulirajočega faktorja, poročali o sindromu kapilarne prepustnosti, ki je lahko smrtno nevaren, če ni zdravljen takoj; glejte poglavje 4.4 in podpoglavje C poglavja 4.8.